J&J antibody benefits RA patients in a midstage study

05/24/2011 | Reuters

Johnson & Johnson's sirukumab, an anti-interleukin-6 monoclonal antibody, elicited a good or moderate response as well as improved symptoms in a majority of patients with rheumatoid arthritis who did not experience substantial relief from methotrexate, according to results of a 12-week Phase II trial. Sirukumab also is being studied among patients with lupus nephritis.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC